Trials / Completed
CompletedNCT00608868
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by EGFR mutation, gender, smoking history, and type of tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | Gefitinib tablet 250mg once daily orally |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-02-06
- Last updated
- 2012-09-28
- Results posted
- 2012-09-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00608868. Inclusion in this directory is not an endorsement.